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Retroviruses have evolved a mechanism for the release of particles from the cell membrane that appropriates cellular protein
complexes, referred to as ESCRT-I, -II, -III, normally involved in the biogenesis of multivesicular bodies. Three diﬀerent classes
of late assembly (L) domains encoded in Gag, with core sequences of PPXY, PTAP, and YPXL, recruit diﬀerent components of
the ESCRT machinery to form a budding complex for virus release. Here, we highlight recent progress in identifying the role of
diﬀerent ESCRT complexes in facilitating budding, ubiquitination, and membrane targeting of avian sarcoma and leukosis virus
(ASLV) and human immunodeﬁciency virus, type 1 (HIV-1). These ﬁndings show that retroviruses may adopt parallel budding
pathways by recruiting diﬀerent host factors from common cellular machinery for particle release.
Copyright © 2009 A. Pincetic and J. Leis. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Due to the small size and content of their genomes, retro-
viruses rely on host cell as much as viral encoded enzymes,
for successful replication. This is particularly evident in
one of the least understood aspects of the retrovirus life
cycle: the assembly and release of virus particles from the
cell surface. When expressed in the absence of other viral
components, Gag (encoding the structural proteins of the
virus) forms virus-like particles (VLPs) that bud from cells,
independent of an active viral-encoded protease (PR). The
assembly process is driven primarily by elements within Gag
[1], such as the membrane-targeting (M) domain, the Gag-
Gag interaction (I) domain necessary for particle formation,
and the late assembly (L) domain required for the separation
of the virion from the host cell membrane. The L domain
recruits an ATP-requiring cellular factor for this scission
event, the only known energy-dependent step in assembly
[2]. Domain is used here to denote the amino acid sequence
that constitutes the biological function.
The ﬁrst suggestions of a virally encoded element
responsible for particle budding came from studies of HIV-1
mutants in which stop codon mutations introduced into the
p6 region of Gag-blocked virion release [3]. The function of
the L domain was subsequently deﬁned in both ASLV and
HIV-1, and mapped to proline-rich sequences in the p2b
[4, 5] and p6 [6] region of Gag, respectively. Single amino
acid substitutions in the PPPY sequence in ASLV Gag or the
PTAP sequence in HIV-1 Gag caused fully assembled virus
particles to accumulate on the cell surface tethered by a thin
membrane stalk. There are now three distinct L domains
identiﬁed and associated with budding defects within the
retrovirus family, with core amino acid motifs of PPxY,
P(T/S)AP, and YPxL [7]. Interestingly, the same L domain
motifs are found in other enveloped virus families (such
as ﬁloviruses, rhabdoviruses, and arenaviruses) [8]. These
similarities suggest that simple enveloped viruses may have
evolved related budding mechanisms for mediating their
r e l e a s ef r o mc e l lm e m b r a n e s .
L domains share a set of characteristics that help deﬁne
their function. First, they exhibit positional independence
in that the peptide motif can be shifted to diﬀerent regions
within Gag without disrupting budding [5, 9]. Second,
they are functionally exchangeable in that the L domain
from one retrovirus can substitute that of another [10].
In some cases, the L domain can function in the context
of diﬀerent virus families [11]. Third, L domains exert
their function in the ﬁnal stages of virion assembly as
evidenced by the delay in proteolytic processing of Gag-
bearing L domain substitutions [6, 12]. These sequences2 Advances in Virology
can thus be deﬁned as protein-binding modules that recruit
the host cell factors that mediate the release of tethered
virus particles from the cell membrane. Though a single L
domain is suﬃcient for particle release for many viruses (i.e.,
ASLV or equine infectious anemia virus (EIAV)), L domain
motifs frequently appear in combinations. For example,
the Mason-Pﬁzer monkey virus (M-PMV) and human T-
cell leukemia virus (HTLV-1) contain tandem PPxY and
PTAPmotifs.HIV-1GagcontainsasecondaryYPX(n)L-type
motif downstream of the PTAP sequence. In the context of
multiple L domains, one motif usually serves a dominant
role in budding. This means that the substitution of the
dominant L domain has a strong eﬀect on blocking budding
while the substitution of the auxiliary L domain has smaller
inhibitoryeﬀectincomparison.ThePPPYmotifisdominant
over the PS/TAP motif in M-PMV [13] and HTLV-1 Gag
[14], and the PTAP motif is dominant over the YPLTSL
motif in HIV-1 Gag [15]. These observations suggest that
diﬀerent types of L domains may dictate diﬀerent budding
pathways, and the presence of multiple L domain motifs
within Gag may provide redundant or synergistic properties
for eﬃcient particle release in the various cell types infected
in vivo.
Many studies have focused on identifying the host
cell factors recruited by each L domain. For HIV-1 Gag,
the dominant PTAP motif binds to Tsg101 [16], and the
secondary YPLTSL motif binds weakly to AIP1/Alix [15, 17,
18]. The YPDL motif of EIAV Gag also binds to AIP1/Alix
[19], though with much greater aﬃnity than HIV-1 Gag
[19, 20]. The PPPY motif of ASLV Gag and murine leukemia
virus (MLV) Gag binds to members of the Nedd4 family of
E3 ubiquitin ligases [21, 22]. Tsg101 and AIP1/Alix belong
to the class E Vps protein family which functions in the
biogenesis of multivesicular bodies (MVBs) in eukaryotic
cells. MVBs are intermediate endosomes that transport
cargo proteins from early to late endosomes for subsequent
degradation in the lysosome. Cargo proteins designated for
degradation are sorted into luminal vesicles of MVBs by
class E Vps proteins in a process topologically equivalent
to virus budding [23]. Genetic screens of Saccharomyces
cerevisiae originally identiﬁed ∼18 class E Vps proteins, most
of which are assembled into three high-molecular weight
cytoplasmic complexes called endosomal sorting complexes
required for transport (ESCRT)-I, -II, and -III. Alignments
with yeast coding sequences revealed that mammalian
cells contain ∼30 orthologues of the class E Vps proteins
implicating a highly conserved MVB pathway for sorting
cargo proteins in eukaryotic cells. Like virus budding, vesicle
formation requires ATP hydrolysis to break attachment to
cellular membranes. The ESCRT-III complex recruits the
AAA ATPase, Vps4, to endosomal membranes to facilitate
membrane scission and recycle membrane-bound ESCRT
complexes to the cytosol [24, 25]. The same Vps4 protein
is required by retroviruses to bud because the coexpression
of a catalytically inactive form of Vps4, Vps4E228Q, arrests
particles at the plasma membrane [26, 27]. These ﬁndings
validate the conclusion that retroviruses, regardless of which
L domain they encode, rely on the ESCRT machinery for
budding.
2. Budding Complexes
The ﬁnding that retroviruses bind to components of a very
specialized protein transport/membrane ﬁssion network
suggests that L domains must recruit a minimal set of
host cell proteins to form a “budding complex” for particle
release. Because retroviruses encode diﬀerent L domains that
directly bind diﬀerent cellular factors, the constituents that
make up the budding complex for each retrovirus may diﬀer.
Figure 1 summarizes the diﬀerences and similarities of the
ASLV and HIV-1 budding pathways. When L domains are
exchanged between retroviruses, the heterologous L domain
confers diﬀerent budding properties on Gag. For example,
the release of wild-type EIAV Gag is resistant to dominant-
negative inhibition by the C-terminal fragment of Tsg101
(Tsg-3 ) and proteasome inhibitors, which normally inhibits
both HIV-1 Gag and MLV Gag. However, replacing the
YPDL L domain of EIAV Gag with the PTAP L domain of
HIV-1 Gag or the PPPY L domain of MLV Gag renders
EIAV sensitive to both Tsg-3  and inhibitor treatment [28].
Presumably, the diﬀerences in budding properties with
heterologous L domains reﬂect the reconstitution of a
parallel budding pathway in which diﬀerent host complexes
are utilized for budding.
The PPPY motif of ASLV Gag binds to a Nedd4-like
E3 ligase to facilitate budding (see Figure 1)[ 21, 29]. There
are ∼10 known members of the Nedd4 family and they
form a subset of a larger contingent of as many as 1500 E3
proteins. The interaction of Nedd4-like proteins with Gag
is mediated by WW motifs which form protein interaction
modules that bind proline-rich sequences 11–14 amino acids
in length. Additionally, Nedd4-like proteins also contain
a C-terminal HECT domain required for the transfer of
ubiquitintothetargetprotein,and,inmostsplicingvariants,
an N-terminal C2, Ca+2-dependent transport domain that
targets E3 proteins to the cell membrane. Coexpression of
an avian Nedd4-like E3 protein made catalytically inactive
by a single amino acid substitution in its HECT domain
inhibits release of ASLV Gag, providing strong evidence
that ubiquitin signaling plays an important role in VLP
release [29]. Yet, translational fusion of ubiquitin to ASLV
Gag failed to rescue particle release in the presence of the
dominant negative avian Nedd4-like fragment called LDI-
1 (C2-WW). This suggests that a full-length Nedd4-like
protein (C2-WW-HECT) contributes in addition critical
functions during release besides the ubiquitination of Gag
[29]. One possibility is that Nedd4-like E3 proteins function
as adaptors to link ASLV Gag to ESCRT components of
the endocytic pathway. Unlike Tsg101 or AIP1, Nedd4-like
proteins are not known to function in MVB biogenesis
in mammalian cells. However, several lines of evidence
suggest that ASLV Gag, like HIV-1 Gag, relies on the ESCRT
machinery for budding. First, expressing the catalytically
inactive Vps4E228Q enzyme inhibits ASLV Gag release in a
dominant-negative fashion [26]. Second, it was previously
established that Nedd4 interacts with Tsg101 [26]. The
relevance of this interaction is supported by the observation
that overexpressing Nedd4L rescues the budding defect
caused by the PTAP deletion in HIV-1 Gag [12, 30]a n dAdvances in Virology 3
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Figure 1: Parallel pathways in ASV and HIV-1 Gag budding. Retroviruses recruit components of the ESCRT machinery to build a budding
complex for particle release. (1) The dominant L domains for HIV-1 and ASV Gag bind to Tsg101 and Nedd4, respectively. Whether this
initial interaction takes place in the cytosol or at the plasma membrane remains to be deﬁned. (2) Nedd4 mediates ubiquitination of ASV
Gag. HIV-1 Gag is ubiquitinated by an unidentiﬁed E3 ligase. Some evidence suggests that Nedd4L may play a role since its overexpression
rescues budding of HIV-1 Gag/ΔPTAP. (3) Gag oligomerization in the cytosol increases membrane avidity and rapidly targets Gag to
sites of assembly/budding on the plasma membrane. ASV Gag assembles on N-Rh-PE-positive, endosome-derived membranes. HIV-1
Gag assembles on N-Rh-PE-negative membranes. (4) During the budding process, Gag may recruit additional ESCRT factors eventually
leading to ESCRT-III polymerization at the base of a budding particle. (5) ESCRT-III subunits recruit the AAA ATPase, Vps4, to mediate
the disassembly of membrane-bound ESCRT complexes and to provide the energy for membrane ﬁssion. (6) VLPs are released from
cellular membranes. Covalently linking ESCRT proteins to the C-terminus of Gag bearing L domain-mutations restores budding at diﬀerent
stages. Tethering Tsg101 to ASV Gag/Δp2b (Δp2b-Tsg101) or HIV-1 Gag/P7L (P7L-Tsg101) rescues budding through an HIV-like pathway
(ESCRT-I-dependent, N-Rh-PE-negative membranes). Tethering EAP20 to ASLV Gag/Δp2b (Δp2b-Eap20) rescues budding through an
ASLV-like pathway (ESCRT-II-dependent, N-Rh-PE-positive membranes). Black arrows indicate wild-type Gag budding pathways. Gray
arrows indicate reconstituted budding pathways of ASLV Gag/Δp2b-ESCRT fusions and HIV-1 Gag/P7L-ESCRT fusions.
thatthisNedd4L-mediatedrescuerequiredTsg101.However,
unlike the budding pathway of wild-type HIV-1 Gag,
Nedd4L-mediated rescue of HIV-1 ΔPTAP release did not
require the PTAP or the ubiquitin-binding ability of Tsg101
[12, 30]. Third, Tsg101 can substitute for the L domain
function of ASLV Gag in promoting eﬃcient VLP release
[31]. Nevertheless, Tsg101 does not normally appear to play
a role in ASLV Gag budding because Tsg101 depletion in
mammalianand/oraviancellsfailstoblockVLPrelease[31].
Finally,multipleNedd4familymemberslocalizetoabnormal
endosomes, called class E compartments, formed in the
presence of Vps4E228Q [22]. These compartments sequester
ESCRT complexes and other proteins associated with the
ESCRT machinery on the limiting endosomal membrane.
Despite these three lines of evidence, the mechanism by
which Nedd4-like proteins link ASLV Gag to downstream
ESCRT factors is not yet understood.
Because L domain motifs link Gag to the ESCRT
machinery, ESCRT proteins can functionally substitute for
these motifs when covalently linked to the C-terminus
of Gag carrying L domain-inactivating substitutions. For
example, Tsg101 rescues HIV-1 Gag budding when tethered
to the C-terminus of HIV-1 Gag/Δp6 (Figure 1)[ 32].
Constructing such Gag-ESCRT chimeras provides a valuable
complementation assay to examine the role of ESCRT
proteins in retrovirus egress. Vps37B [33] and Vps37C [34]4 Advances in Virology
also rescue budding of HIV-1 Gag/P7L (an inactivating
PTAP substitution) conﬁrming the view that HIV-1 requires
ESCRT-Iactivityforrelease.WhenproteinsfromtheESCRT-
II and -III complexes are fused to HIV-1 Gag/P7L, only the
ESCRT-III protein, Chmp6, restored eﬃcient VLP release
(see Figure 1)[ 34]; the ESCRT-II proteins, Eap20 and
Eap45, failed to rescue particle release which correlates with
previous reports that HIV-1 Gag does not require ESCRT-
II proteins [35]. In contrast, Eap20 partially complements
the Δp2b deletion when conjugated to the C-terminus of
ASLV Gag/Δp2b. This suggests a functional requirement
for ESCRT-II in ASLV Gag budding (see Figure 1). In
support of this view, siRNA-mediated depletion of Eap20,
which does not interfere with HIV-1 Gag budding, potently
inhibits the release of ASLV Gag VLPs [34]. This is the ﬁrst
demonstration of the ESCRT-II complex participating in
retrovirus budding. The ﬁnding that HIV-1 and ASLV Gag
diﬀer in their requirement for ESCRT-I and -II complexes
supports the hypothesis that diﬀerent L domains specify the
use of diﬀerent ESCRT complexes during budding.
Retroviruses that are sensitive to dominant-negative
Vps4 most likely share a common requirement for ESCRT-
III. The ESCRT-III complex consists of ∼11 CHMP proteins
characterizedassmall,highly-chargedcoiled-coil-containing
proteins that oligomerize into an array on endosomal
membranes. Charged MVB proteins (CHMPs) contain a
highly basic N-terminus and an acidic C-terminus, which
allows these proteins to adopt either an “open” or “closed”
conformation [36]. In its monomeric (“closed” or autoin-
hibited) state, an acidic C-terminal helix binds the basic N-
terminal interface responsible for membrane binding and
oligomerization. In experimental settings, deletion of the
acidic C-terminal helix of multiple CHMPs results in the
formation of an insoluble membrane-bound polymer that
disrupts MVB biogenesis and retrovirus budding [25, 34,
36, 37]. The C-terminus of CHMPs also contains protein-
binding sites for upstream factors of the ESCRT machinery,
such as Eap20 and AIP1/Alix. This raises the possibility
that protein binding displaces the autoinhibitory C-terminal
helix to promote ESCRT-III array formation. Interestingly,
this “open” conformational state exposes an MIT-interacting
motifthatallowsESCRT-IIItorecruitVps4.ThoughESCRT-
I and -II may function in sorting cargo to MVBs, ESCRT-
III polymerization may function in vesicle formation and
membrane scission. A recent study using quick-freeze deep-
etch electron microscopy demonstrated that overexpressed
CHMP4 polymerized on the plasma membrane and endo-
somes as curved ﬁlaments assembled into a circular array
[38]. When coexpressed with Vps4BE235Q, the CHMP4
polymers formed buds and tubules in which the membrane
folded away from the cytoplasm [38]. Similarly, C-terminally
deleted fragments of CHMP2A and CHMP3 coassembled
into helical tubular structures in vitro, in which the
membrane-binding site was exposed on the outside surface
and the Vps4-binding site was enclosed within the hollow
tube [39, 40]. When the CHMP2A/3 tubules were assembled
in vitro with Vps4B, Vps4B was oligomerized on the inside
of the tubes. In the presence of ATP, Vps4B catalyzed the
disassembly of these structures [39, 40]. In the context of
retrovirus budding, Gag oligomerization may be suﬃcient
for membrane deformation. ESCRT-III may facilitate Vps4
recruitment to the site of assembly in order to provide the
energyrequiredformembranescission.DeﬁningtheESCRT-
III subunits required for retrovirus budding is an active area
of research. However, assessing the role of ESCRT-III sub-
units has proven diﬃcult thus far. Dominant-negative forms
of various ESCRT-III proteins, in which the C-terminal
autoinhibitory domain is deleted, display potent inhibition
ofHIV-1andASLVGagrelease[34,36].Whetherdominant-
negativeinterferencebyESCRT-IIIfragmentsreﬂectsadirect
interferenceoftheretrovirusbuddingcomplexoranindirect
sequestration of necessary cofactors is not known. Similarly,
siRNA-mediated knockdown of various ESCRT-III proteins
has yielded limited insights to date [34, 35]. Whether siRNAs
fail to suﬃciently deplete endogenous proteins or if ESCRT-
III contains redundant mechanisms is unclear.
3.PositiveSorting Signals
Currentresearchrecognizesthatmonoubiquitinandcharged
lipids provide critical sorting signals for the recruitment and
activation of ESCRT complexes. Similarly, retroviruses rely
on these sorting signals to complete the budding process.
Ubiquitin, a 76-amino acid protein, regulates several
cellular processes ranging from proteasome-mediated degra-
dation to DNA repair to protein transport. Posttranslational
attachment of a single ubiquitin moiety (i.e., monoubiqui-
tin) serves as a signal for transmembrane protein internal-
ization and sorting through the endocytic pathway. Several
endocytic proteins contain ubiquitin-binding domains to
recognize the monoubiquitin sorting signal [23]. The ﬁrst
endocytic protein to sense ubiquitinated cargo during MVB
biogenesis is the class E Vps protein, Hrs, which forms part
of the Hrs-Stam complex. The Hrs-Stam complex localizes
to early endosomes (through the FYVE domain of Hrs)
to direct ubiquitinated cargo to the limiting membrane of
late endosomes. Hrs also interacts with Tsg101, and recruits
ESCRT-I to the endosomal membrane. ESCRT-I initiates
the recruitment of downstream components of the MVB
pathway, such as ESCRT-II, AIP1/Alix, or ESCRT-III, to the
limiting endosomal membrane. Importantly, both ESCRT-I
and -II contain ubiquitin-binding domains that may allow
for sorting and concentration of ubiquitinated cargo at the
site of vesicle formation. Though ESCRT-III proteins do not
bind ubiquitin, several bind to deubiquitinating enzymes,
such as AMSH and UBPY, to remove ubiquitin from cargo
proteins prior to membrane scission [41].
In addition to ubiquitin, lipid sorting also plays an
important role in establishing appropriate platforms for
MVB biogenesis. Unlike the limiting endosomal membrane,
vesicle membranes must be susceptible to the hydrolytic
environment for degradation. Several observations suggest
that the lipid phosphatidylinositol 3-phosphate (PI(3)P)
provides critical functions for vesiculation [42]. PI(3)P
localizes to the cytoplasmic leaﬂet of early endosomes
and internal vesicles of MVBs. Several proteins along the
endocytic pathway, such as Hrs, Eap45 (ESCRT-II), andAdvances in Virology 5
Chmp4 (ESCRT-III), contain PI(3)P-binding domains for
localization to sites of MVB biogenesis [23]. Inhibitors of
PI 3-kinases, the enzymes that phosphorylate phosphatidyli-
nositols to produce PI(3)P, prevent vesiculation and cause
cargo proteins, such as EGFR, to remain trapped on the
limiting membrane of MVBs [43]. In addition to PI(3)P,
other lipids, including cholesterol and lysobisphosphatidic
acid (LBPA), function in the subdomain organization and
eﬀector protein recruitment [23, 42].
Ubiquitin. The ﬁrst indications that ubiquitin might play a
role in retrovirus replication came from studies in which
puriﬁed ASLV particles were found to contain a signiﬁcantly
greater concentration of unconjugated ubiquitin than that
present in the cytosol [44]. The fact that the relative
amounts of other low molecular weight host protein were
not increased suggested that ubiquitin was selectively incor-
porated into virions [44]. Subsequently, studies with HIV-1,
simianimmunodeﬁciencyvirus(SIV),andMLVGagveriﬁed
that ∼2–5% of Gag in VLPs were monoubiquitinated [45].
Additionally, the ubiquitin moieties were covalently attached
to the L domain-encoding p6 and p12 peptides of HIV-
1/SIVandMLVGag,respectively[45].Thisﬁndingcorrelates
with several observations that Gag is ubiquitinated in an L
domain-dependent manner. Several lines of evidence point
to a role for ubiquitin in the budding process: (1) depleting
solubleubiquitinbytreatingcellswithproteasomeinhibitors
causes a late budding defect for most retroviruses [46, 47].
Fusing ubiquitin to the C-terminus of ASLV Gag rescues
budding in the presence of inhibitor treatment [48]; (2)
substitutions of lysine residues in close proximity to the
L domain of HIV-1, ASLV, and HTLV-1 Gag inhibit VLP
release [49–51]; (3) as mentioned previously, overexpressing
catalytically inactive Nedd4-like E3 ligases inhibit budding
of PPxY-dependent retroviruses [22, 29]; (4) overexpressing
ubiquitin bearing mutations in hydrophobic residues that
regulate endocytic signaling also inhibit HIV-1 Gag release
[52].
Despite the known requirement for ubiquitin in retrovi-
ral budding pathways, the mechanistic function of ubiquitin
remains unsolved. One model posits that ubiquitination of
Gag allows for increased aﬃnity between Gag and ESCRT
components required for budding, speciﬁcally ESCRT-I and
-II complexes. For example, the ubiquitin-binding domain
of ESCRT-I resides within the N-terminal UEV domain of
Tsg101, the host factor that binds the PTAP motif of HIV-1
Gag. Ubiquitination of the p6 region of HIV-1 Gag actually
increases its binding aﬃnity to Tsg101 [53]. Conversely,
deleting the Ub-binding pocket within the UEV domain
of Tsg101 potently inhibits the release of HIV-1 Gag [54].
Further evidence for the role of ubiquitin in facilitating
assemblyofGag/ESCRTcomplexescomesfromobservations
that fusion of ESCRT-I and -II proteins to the C-terminus
of ASLV Gag/Δp2b not only rescued budding of Gag, but
also restored ubiquitin modiﬁcation that was lost upon the
deletion of the L domain (see Figure 1)[ 34]. A fraction
of the Gag-ESCRT chimeras incorporated into VLPs was
monoubiquitinated [33, 34]. Interestingly, fusion of the
ESCRT-III subunit, Chmp6, failed to restore ubiquitination
of the Gag/Δp2b-ESCRT chimera despite its low level of
budding [34]. These ﬁndings indicate that (i) eﬃcient
budding of VLPs correlates with ubiquitin modiﬁcation,
and (ii) ubiquitination also coincides with the utilization of
ESCRT-I and/or -II complexes during budding. This latter
point is consistent with the fact that only the ESCRT-I and
-II complexes contain known ubiquitin-binding elements
capable of recognizing this sorting signal. In fact, a recent
study showed that fusing ubiquitin to the C-terminus of
the L domain-deﬁcient EIAV Gag/ΔYPDL rescued particle
production in a Tsg101-dependent budding pathway [55].
Budding rescue relied on the surface-exposed hydrophobic
residues on ubiquitin that mediate the interaction with
ubiquitin-binding domains found in Tsg101 and, possibly,
AIP1/Alix [55].
Other observations oﬀer alternative roles of ubiquitin
in retrovirus budding. For example, ubiquitin fusion to the
C-terminus of EIAV Gag/ΔYPDL sensitized VLP release to
proteasomeinhibitors[55].Thissuggeststhatubiquitination
of factors other than Gag may be necessary for particle
release.Additionally,theGagproteinoftheprototypicfoamy
virus (PFV), which encodes a PSAP L domain, contains
a single lysine residue that bears no requirement for VLP
release [56]. Replacing the PSAP motif of PFV Gag with the
PPPY motif of MLV Gag renders this chimeric PFV Gag-PY
construct dependent on Nedd4-like E3 ligases for budding.
Yet,buddingremainsunaﬀectedwhensubstitutingthesingle
ubiquitin acceptor site from this PFV Gag-PY construct [56].
These ﬁndings suggest that ubiquitination of Gag is not
necessary for particle release. It should be noted, however,
that PFV exhibits unusual assembly properties since capsids
assemble in the cytosol and VLPs are only released when Gag
is coexpressed with Env. The PFV Gag constructs described
by Zhadina et al. appended artiﬁcial membrane-targeting
domains to the N-terminus of PFV Gag to eliminate the
requirement for Env coexpression in VLP production.
Lipids. The current model proposes that the M domain,
located within the matrix regions of Gag, mediates plasma
membrane binding for assembly and budding. For most
retroviruses, the M domain signal consists of a series of
conserved basic residues and an N-terminal acyl group,
typically myristate, covalently attached upon translation.
Several cellular proteins are known to bind membranes
through a myristyl switch mechanism, in which a con-
formational change triggers the exposure of myristate to
promote membrane association [57, 58]. Strong evidence
supports the view that myristylated Gag interacts with
membranes through a similar mechanism [59–61]. For
example, monomeric Gag of HIV-1, which binds mem-
branes poorly, sequesters the N-terminal myristate moiety
within the MA globular domain. Gag oligomerization in
the cytosol coincides with myristate exposure, drastically
increasing membrane aﬃnity. The cluster of basic amino
acids in MA appears to impart speciﬁcity to membrane
binding.Substitutionofthesebasicresiduesimpedesparticle
release by misdirecting Gag assembly toward intracellular6 Advances in Virology
membrane platforms [62]. Possibly, the basic domain within
MA interacts with host cell factors to determine the site
of assembly and budding. Cells contain multiple variations
of phosphatidylinositols (PI), classiﬁed by the number and
position of phosphate groups attached to the inositol ring.
Diﬀerent PIs localize to diﬀerent subcellular compartments
to direct proteins to speciﬁc sites of action. PI(4,5P2,a l o n g
with PI(3,4,5)P3, accumulates on the cytoplasmic leaﬂet
of the plasma membrane. Recent ﬁndings point to the
lipid phosphatidylinositol (4,5)-bisphosphate (PI(4,5)P2)i n
regulating HIV-1 Gag traﬃcking to the plasma membrane
[63]. Depleting PI(4,5)P2 in HeLa cells by overexpressing PI-
5-phosphatase IV (5-ptase IV) reduced HIV-1 Gag budding
and targeted Gag to CD63-positive late endosomes [64]. A
recently described NMR structure of the myristylated HIV-
1 MA protein demonstrates that the 2 fatty acid chain of
PI(4,5)P2 occupies a hydrophobic cavity within MA, and
that the negatively charged phosphate groups on the inositol
ring interact with basic residues in MA.Similar ﬁndings were
reported for the MA protein of the related retrovirus, EIAV
[65]. Critically, PI(4,5)P2 binding changes the conformation
of Gag such that the myristyl group becomes exposed,
thereby coupling plasma membrane binding to assembly
[66].
The transport signal for ASLV Gag may diﬀer from
HIV-1Gagassuggestedbythedisparatelocalizationpatterns
observed for ﬂuorescent-tagged ASLV Gag-GFP and HIV-1
Gag-RFPwhencoexpressedinmammaliancells.[67].Unlike
the myristyl switch of HIV-1, ASLV MA relies only on the
patch of basic residues for membrane binding. However,
recent observations also suggest that ASLV Gag associates
with speciﬁc membrane components to determine the site of
assembly and budding. Though phosphatidylethanolamine
(PE) is a major component of the plasma membrane, the
lipid analog N-Rh-PE is a lipid marker for endocytic vesicles
because it forms small molecular clusters when present in
membranes [57]. Molecular aggregation has been proposed
to function as an additional positive sorting signal for
lysosomal targeting since membrane components may be
targeted to the lysosome when induced to aggregate. The
presence of a rhodamine ﬂuorophore on the head group
of N-Rh-PE enables the visualization of endosome-derived
membranes by confocal microscopy [68, 69]. When VLPs are
puriﬁed from COS cells treated with N-Rh-PE, ASLV Gag-
GFP particles contain the lipid analog in their envelope (see
Figure 1)[ 31]. Interestingly, HIV-1 Gag VLPs fail to incor-
porate N-Rh-PE [31]. These ﬁndings suggest that ASLV Gag
and HIV-1 Gag bud through diﬀerent membrane regions,
with ASLV Gag passing through an endosome-derived
membrane at some point during the assembly process (see
Figure 1). Furthermore, ASLV Gag appears to associate with
N-Rh-PE-positive membranes in an L domain-dependent
manner. Unlike VLPs assembled from WT Gag, the VLPs
assembled from ASLV Gag/Δp2b do not incorporate N-Rh-
PE or the tetraspanin protein CD63 (a protein marker of
the LE/MVB compartment) [31]. The ﬁnding that the L
domain may contribute to membrane targeting of Gag was
surprising because L domains are not typically thought to
play a role in transport. Unlike the C-terminal p6 or p9
regions of HIV-1 or EIAV Gag, respectively, factors recruited
by the N-terminal p2b region of ASLV may cooperate with
the M domain to form the transport signal. Possibly, the
C2 transport domain of Nedd4-like proteins may function
in concert with the M domain signal. Alternatively, ASLV
may utilize the membrane-binding activity of the ESCRT
complexes to associate with N-Rh-PE-positive membranes.
In support of this view, VLPs assembled from the chimeric
Gag construct, ASLV Gag/Δp2b-Eap20, incorporated the N-
Rh-PE tracer into the envelope (see Figure 1)[ 31]. When
ASLV Gag adopts a Tsg101-dependent budding pathway, as
in the case of the Gag-ESCRT-I fusions (ASLV Gag/Δp2b-
Tsg101 or −Vps37C), VLPs failed to incorporate N-Rh-
PE (see Figure 1)[ 31]. This directly demonstrates that
factors recruited by diﬀerent L domains confer diﬀerent
budding properties on Gag. Similar to the exchange of L
domains, alteration of the proteins that form the budding
complex (i.e., substituting Tsg101/Vps37C for Nedd4-like
E3s) redirects Gag toward an alternate budding pathway.
4. Conclusion
Substantial progress has been made in recent years to
elucidate the role of diﬀerent ESCRT complexes in retrovirus
budding and to understand the role that monoubuiqitina-
tion of Gag plays in assembling the budding complexes.
However, fundamental questions still remain. For example,
after structural and biochemical data allowed for better
understanding of the ESCRT-I and ESCRT-II complexes,
the focus now turns to ESCRT-III. How do ESCRT-
III subunits oligomerize on membranes? What signals
regulate this oligomerization? Which ESCRT-III proteins
are required for retrovirus budding? Novel strategies may
be required to answer this latter question, as dominant-
negative interference and siRNA-mediated knockdown of
various CHMPs appear inadequate. Furthermore, additional
questions remain about the role of ubiquitin in retrovirus
budding. Is monoubiquitin modiﬁcation of Gag a necessary
aspect of the budding pathway or merely a byproduct of
the ESCRT complexes associating with ubiquitination appa-
ratus? The requirement for monoubiquitin may depend on
whichretrovirusesrecruithost factorscapableofrecognizing
the ubiquitin signal, and may not be a universal requirement
for budding. One unifying theme seems clear: retroviruses
may utilize parallel budding pathways by co-opting diﬀerent
components of the ESCRT machinery to reach the same end
point, that is, Vps4-dependent release of particles from the
plasma membrane.
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